KUN-HUEI YEHShiou-Hwei YehChang Y.-S.ANN-LII CHENG2021-01-282021-01-2820000901-9928https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034017692&doi=10.1034%2fj.1600-0773.2000.pto860305.x&partnerID=40&md5=0195c4260df4640f6170c2568f3439bahttps://scholars.lib.ntu.edu.tw/handle/123456789/543553Although very high doses of 5-fluorouracil was used in the weekly 24-h infusion, high-dose 5-fluorouracil (2600 mg/m2/week) and leucovorin (500 mg/m2/week) protocol, myelosuppression was surprisingly low. The current study was conducted to investigate the possible mechanism underlying the low myelosuppression. To mimic the clinical situation, peripheral blood progenitor cells collected from 12 patients were used for colony forming unit-granulocyte and monocyte clonogenic assay; and 2 representative models of 5-fluorouracil exposure (30 min. versus 24 hr) were examined for cytotoxic effects on human myeloid progenitor cells. Previous pharmacokinetic studies have estimated the concentration of 5-fluorouracil in the bone marrow to be 200-400 μM and 1-2 μM for the 30 min. infusion (600-900 mg/m2) and the 24 hr-infusion (1000-2000 mg/m2) regimens, respectively. The results of our colony-forming unit-granulocyte and monocyte clonogenic assay showed that 24- hr exposure to 5-fluorouracil (2 μM) and 30 min. exposure to 5-fluorouracil (100 μM) resulted in 27.2% and 78.2% inhibition of the colony formation, respectively. Our data provided direct evidence which may explain why myelotoxicity is significantly less in weekly 24 hr infusion of fluorouracil than in the conventional bolus regiments.[SDGs]SDG3antineoplastic agent; fluorouracil; folinic acid; acute leukemia; adult; article; bone marrow suppression; bone marrow toxicity; breast cancer; cancer chemotherapy; clinical article; colony forming unit GM; cytotoxicity; dose response; drug megadose; female; human; human cell; lymphoma; male; priority journal; promyelocytejournal article10.1034/j.1600-0773.2000.pto860305.x107526692-s2.0-0034017692